March 29, 2018 / 1:34 PM / 25 days ago

BRIEF-Actobio Therapeutics Greenlighted By FDA To Commence A Phase Ib/Iia Trial With AG019

March 29 (Reuters) - Intrexon Corp:

* ACTOBIO THERAPEUTICS GREENLIGHTED BY FDA TO COMMENCE A PHASE IB/IIA TRIAL WITH AG019 FOR THE TREATMENT OF EARLY ONSET TYPE 1 DIABETES

* ACTOBIO THERAPEUTICS SAYS “SOON WILL START CLINICAL TRIALS” WITH AG019 “IN ASSOCIATION WITH SPECIALIZED INSTITUTES IN EUROPE AND NORTH AMERICA” Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below